Am J Psychiatry 161:1692-1697, September 2004
© 2004 American Psychiatric Association
Safety Reporting in Randomized Trials of Mental Health Interventions
Panagiotis N. Papanikolaou, M.D.,
Rachel Churchill, M.Sc.,
Kristian Wahlbeck, M.D., Ph.D., and
John P.A. Ioannidis, M.D. The EU-PSI Project
OBJECTIVE: The authors aimed to evaluate the adequacy of the reporting of safety information in publications of randomized trials of mental-health-related interventions. METHOD: The authors randomly selected 200 entries from the PsiTri registry of mental-health-related controlled trials. This yielded 142 randomized trials that were analyzed for adequacy and relative emphasis of their content on safety issues. They examined drug trials as well as trials of other types of interventions. RESULTS: Across the 142 eligible trials, 103 involved drugs. Twenty-five of the 142 trials had at least 100 randomly chosen subjects and at least 50 subjects in a study arm. Among drug trials, only 21.4% had adequate reporting of clinical adverse events, and only 16.5% had adequate reporting of laboratory-determined toxicity, while 32.0% reported both the numbers and the reasons for withdrawals due to toxicity in each arm. On average, drug trials devoted 1/10 of a page in their results sections to safety, and 58.3% devoted more space to the names and affiliations of authors than to safety. None of the trials of nondrug interventions had adequate or even partially adequate reporting of either clinical adverse events or laboratory-determined toxicity. In multivariate modeling, long-term trials and trials conducted in the United States devoted even less space to safety, while schizophrenia trials devoted more space to safety than did trials in other areas. CONCLUSIONS: Safety reporting is largely neglected across trials of mental-health-related interventions, thus hindering the assessment of risk-benefit ratios for rational decision making in mental health care.
This article has been cited by other articles:
|
|
|
|
 
S. Leucht, S. Heres, J. Hamann, and J. M. Kane
Methodological Issues in Current Antipsychotic Drug Trials
Schizophr Bull,
March 1, 2008;
34(2):
275 - 285.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Hodgson, C. Bushe, and R. Hunter
Measurement of long-term outcomes in observational and randomised controlled trials
The British Journal of Psychiatry,
August 1, 2007;
191(50):
s78 - s84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Ethgen, I. Boutron, G. Baron, B. Giraudeau, J. Sibilia, and P. Ravaud
Reporting of Harm in Randomized, Controlled Trials of Nonpharmacologic Treatment for Rheumatic Disease
Ann Intern Med,
July 5, 2005;
143(1):
20 - 25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Chou and M. Helfand
Challenges in Systematic Reviews That Assess Treatment Harms
Ann Intern Med,
June 21, 2005;
142(12_Part_2):
1090 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P.A. Ioannidis, S. J.W. Evans, P. C. Gotzsche, R. T. O'Neill, D. G. Altman, K. Schulz, D. Moher, and for the CONSORT Group*
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ann Intern Med,
November 16, 2004;
141(10):
781 - 788.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Caveat Lector: Where's the Safety Information in Medication Trials?
Journal Watch Psychiatry,
October 6, 2004;
2004(1006):
1 - 1.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2004
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
